NCT03459079
52 evidence topics · 6 sources
Objective
Aim stated in the published report
Location and study date
Study dates and location in the ClinicalTrials.gov record
“Study Start (Actual) 2018-08-14” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2023-04-18” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2023-06-01” (opens the source at this quote in a new tab)
“This study has 1 location” (opens the source at this quote in a new tab)
“Gainesville, Florida, United States, 32610” (opens the source at this quote in a new tab)
Results posting date in the ClinicalTrials.gov results
Site, recruitment sources, and enrollment period in the published report
Study design
Single-center, double-blind, placebo-controlled design in the published report
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Interventional model description | “A two arm randomized (1:1), double-blind, placebo-controlled, trial.” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |
| Phase | “Phase 2” |
Run-in, treatment, and follow-up periods in the ClinicalTrials.gov record
Visits and end-of-treatment assessments in the published report
Healthy control group for metabolic and imaging reference values
Funding by Inventiva and role of the funder
Eligibility criteria
Key inclusion and exclusion criteria in the published report
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record: other liver disease, alcohol, insulin or pioglitazone, CYP2C8 interacting drugs, and BMI
Population not selected for fibrosis stage F2 or higher
Treatment
Lanifibranor and placebo tablets in the ClinicalTrials.gov record
Dose, administration with food, dose selection, and comparator in the protocol
Background antidiabetic therapy and run-in titration in the ClinicalTrials.gov record
Study outcomes
Rationale for using intrahepatic triglyceride content by proton magnetic resonance spectroscopy as the primary endpoint
Primary endpoint as registered
Primary endpoint in the protocol and the published report
Proton magnetic resonance spectroscopy as the reference imaging method
Thresholds for liver fat response and resolution and their assumed relation to histology in the protocol
Relation of steatosis to insulin resistance and to histological response in the published report
Secondary endpoints: insulin sensitivity by clamp, IHTG response, cardiometabolic parameters, and liver stiffness
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size revised on the basis of NATIVE steatosis results in the protocol
Reduction of the planned number of participants stated in the ClinicalTrials.gov results
Registry actual enrollment of 128 and 38 randomized participants
Randomized participants, full analysis set, and completers in the published report and the poster
Randomized participants in the company topline release
Description of analysis sets
Analysis sets defined in the protocol
Analysis sets, statistical tests, multiplicity, and missing data in the published report
Results
Participant disposition
Participant flow by group in the ClinicalTrials.gov results
“Started 20 18 10” (opens the source at this quote in a new tab)
“Completed 14 14 10” (opens the source at this quote in a new tab)
“Not Completed 6 4 0” (opens the source at this quote in a new tab)
“Adverse Event 4 2 0” (opens the source at this quote in a new tab)
“Withdrawal by Subject 2 2 0” (opens the source at this quote in a new tab)
Completion and reasons for discontinuation in the published report
Baseline characteristics
Baseline clinical and laboratory characteristics, FAS (published report)
| Characteristic | Placebo (n = 18) | Lanifibranor (n = 20) |
|---|---|---|
| Age, years (mean ± SD) | “58 ± 11” | “61 ± 7” |
| Gender (% male/female) | “28/72” | “45/55” |
| White, n (%) | “15 (83%)” | “18 (90%)” |
| Weight, kg (mean ± SD) | “99 ± 20” | “96 ± 14” |
| Body mass index, kg/m2 (mean ± SD) | “34.3 ± 6.2” | “33.8 ± 5.1” |
| Fasting plasma glucose, mg/dl (mean ± SD) | “122 ± 22” | “130 ± 26” |
| HbA1c, % (mean ± SD) | “7.0 ± 0.8” | “6.8 ± 0.5” |
| Fasting plasma insulin, μU/ml (mean ± SD) | “18.2 ± 12.7” | “16.4 ± 8.6” |
| Triglycerides, mg/dl (mean ± SD) | “196 ± 101” | “175 ± 95” |
| HDL-C, mg/dl (mean ± SD) | “43 ± 12” | “42 ± 9” |
| Alanine aminotransferase, U/L (mean ± SD) | “35 ± 27” | “37 ± 20” |
| Aspartate aminotransferase, U/L (mean ± SD) | “31 ± 19” | “31 ± 14” |
| HOMA-IR (mean ± SD) | “5.4 ± 3.4” | “5.6 ± 3.2” |
| Adiponectin, μg/ml (mean ± SD) | “5.0 ± 3.7” | “4.5 ± 2.8” |
| Intrahepatic triglyceride content, % (mean ± SD) | “18 ± 7” | “21 ± 7” |
| Liver stiffness by MRE, kPa (mean ± SD) | “2.5 ± 1.1” | “2.8 ± 0.8” |
Mean baseline HbA1c stated in the discussion of the published report
Baseline cT1, CAP, and LSM (poster)
| Characteristic | Lanifibranor (N=20) | Placebo (N=18) |
|---|---|---|
| Baseline corrected T1 mapping, ms | “887 ± 72” | “924 ± 116” |
| Baseline CAP, db/m | “356 ± 36” | “352 ± 28” |
| Baseline LSM, kPa | “8.3 ± 4.6” | “8.2 ± 7.2” |
Efficacy results
Primary endpoint: absolute change in IHTG at week 24, FAS and completers (published report)
Relative change in IHTG, IHTG reduction of at least 30%, and steatosis resolution, FAS and completers (published report)
IHTG endpoints at week 24 (registry)
| Outcome | Lanifibranor (n = 20) | Placebo (n = 18) |
|---|---|---|
| Absolute change in IHTG, LS mean (95% CI) | “-8.7 (-11.3 to -6.0)” | “-3.0 (-5.9 to -0.2)” |
| IHTG decrease of ≥30%, % of participants (95% CI) | “65 (41 to 85)” | “22 (6 to 48)” |
| NAFLD resolution (IHTG ≤5.5%), % of participants (95% CI) | “25 (9 to 49)” | “0 (0 to 19)” |
Secondary metabolic endpoints at week 24, FAS adjusted LS means (published report)
Hepatic glucose production and muscle glucose disposal, completers (published report)
Liver stiffness by transient elastography and MRE and plasma cytokeratin-18 at week 24 (registry)
| Outcome | Lanifibranor | Placebo |
|---|---|---|
| Liver stiffness by vibration controlled transient elastography, absolute change in kPa, LS mean (95% CI); n = 20 and 18 | “-1.49 (-2.66 to -0.31)” | “-0.34 (-1.57 to 0.9)” |
| Liver stiffness by MRE, change in kPa, LS mean (95% CI); n = 18 and 18 | “0.23 (0.03 to 0.42)” | “-0.06 (-0.25 to 0.13)” |
| Plasma cytokeratin 18, absolute change in IU/L, mean (SD); n = 20 and 18 | “-130.71(164.28)” | “-70.21(230.39)” |
Primary endpoint as reported in the 2023 congress poster, FAS and completers
Topline results, FAS and completers (company release, June 2023)
“Full Analysis Set (N=38)” (opens the source at this quote in a new tab)
“Completers (N=28)” (opens the source at this quote in a new tab)
“June 13, 2023” (opens the source at this quote in a new tab)
| Completers, change from baseline to week 24 | Placebo (n=14) | Lanifibranor 800 mg (n=14) |
|---|---|---|
| Absolute change in HbA1c, % | “-0.2%” | “-0.9” |
| Absolute change in fasting plasma insulin, μU/ml | “-1.0” | “-6.7” |
| Absolute change in hepatic insulin resistance index | “-9.5” | “-30.1” |
| Absolute change in basal endogenous glucose production (mg/kgLBM/min) | “0.1” | “-0.5” |
| Absolute change in muscle insulin-stimulated glucose disposal (mg/kg LBM/min) | “-0.2” | “+2.2” |
| Absolute change in HDL-C, mg/dl | “-0.3” | “6.3” |
| Absolute change in adiponectin, μg/mL | “-0.2” | “7.5” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Weight gain, adverse events, and discontinuations (published report)
Treatment-emergent adverse events by group (published report)
| Event, n (%) | Placebo (n = 18) | Lanifibranor (n = 20) |
|---|---|---|
| Patients with TEAEs | “17 (94%)” | “18 (90%)” |
| Patients with severe TEAEs | “0 (0%)” | “1 (5%)” |
| Patients with serious adverse events | “0 (0%)” | “1 (5)” |
| TEAEs leading to drug discontinuation | “2 (11%)” | “4 (20%)” |
| Drug-related TEAE leading to discontinuation | “2 (11%)” | “3 (15%)” |
| Diarrhea | “3 (17%)” | “5 (25%)” |
| Elevated lipase level | “3 (17%)” | “5 (25%)” |
| Anemia | “2 (11%)” | “4 (20%)” |
| Leukopenia | “1 (6%)” | “3 (15%)” |
| Headache | “1 (6%)” | “3 (15%)” |
| Arthralgia | “3 (17%)” | “0 (0%)” |
| Oedema | “0 (0%)” | “1 (5%)” |
| Hypoglycemia | “0 (0%)” | “1 (5%)” |
| Decrease in eGFR | “2 (11%)” | “1 (5%)” |
Weight change in kilograms, edema, hemoglobin, and lipase (poster)
Mortality, serious adverse events, and selected other adverse events over 28 weeks (registry)
| Event, affected / at risk (%) | Lanifibranor | Placebo |
|---|---|---|
| All-cause mortality | “0/20 (0.00%)” | “0/18 (0.00%)” |
| Serious adverse events, total | “1/20 (5.00%)” | “0/18 (0.00%)” |
| Other (not including serious) adverse events, total | “18/20 (90.00%)” | “17/18 (94.44%)” |
| Anaemia | “4/20 (20.00%)” | “2/18 (11.11%)” |
| Diarrhoea | “5/19 (26.32%)” | “3/18 (16.67%)” |
| Elevated lipase level | “5/20 (25.00%)” | “3/18 (16.67%)” |
| Edema | “1/20 (5.00%)” | “0/18 (0.00%)” |
Study limitations
Summary: design, sample size, and enrolled population
- The trial was single-center (Gainesville, Florida) and investigator-initiated, with financial support from Inventiva; the Inventiva research and development team had access to the database lock and assisted in the final analysis.
- The planned number of participants was reduced during the trial on the basis of NATIVE steatosis results, to 15 per group completing treatment (power 0.80) and 33 to 34 randomized. A total of 38 participants were randomized (20 lanifibranor, 18 placebo), and 28 completed 24 weeks (14 [70%] and 14 [78%]). The registry states that the COVID epidemic greatly impacted recruitment and promoted dropout. The registry enrollment of 128 counts all enrolled participants, of whom 38 were randomized and 10 were healthy controls.
- The registry gave an estimated recruitment period of about 9 months; randomization took place between August 2018 and April 2023.
- The authors state that the study did not seek to recruit patients with MASH (fibrosis stage ≥F2) or to assess the role of improving insulin resistance on liver histology, for which the study was “not statistically powered”. The protocol states that the liver fat thresholds are assumed to correlate with histological changes based on the investigator's experience.
- The discussion of the published report describes mild hyperglycemia with a mean baseline HbA1c of 7.2%; the baseline table gives 7.0 ± 0.8% with placebo and 6.8 ± 0.5% with lanifibranor. The male/female percentages at baseline were 28/72 with placebo and 45/55 with lanifibranor.
Summary: missing-data handling, multiplicity, and figures that differ by source
- For missing week 24 IHTG data, the primary analysis used the baseline value under stated conditions; missing categorical data were imputed as failure, and missing data for the secondary metabolic endpoints were imputed by last observation carried forward.
- The protocol defined no plan to control multiplicity for secondary or exploratory endpoints, which are considered exploratory.
- The absolute change in IHTG differs by source. The 2023 congress poster reports -10.1% with lanifibranor versus -1.4% with placebo in the FAS and -12.4% versus -2.4% in completers; the published report gives -8.7% versus -3.0% (FAS) and -10.8% versus -4.0% (completers), and the registry gives -8.7 and -3.0. Both the poster and the published report give LS mean differences of -5.6% (FAS) and -6.9% (completers).